Table V.

CT antigen expression in patients with poorly differentiated and anaplastic carcinomas.

P	Gender	Age	Disease	Size (cm)	Tumor stage	Positive lymph node	Metastasis	Angiolymphatic invasion	Extra-thyroidal extension	Multi MAGE-A	CT7 (MAGE-C1)	GAGE	CTAG1B
1	M	61	anaplastic	2.0	T4aN0M0	No	No	No	No	f	f	f	–
2	M	73	anaplastic	1.5	T4aN0M0	No	No	No	No	f	f	–	–
3	F	82	anaplastic	0.8	T4bN0M0	No	No	Yes	Yes	4+	f	f	–
4	F	83	anaplastic	4.7	T4bN0M0	No	No	Yes	Yes	–	–	–	–
5	M	53	anaplastic	1.2	T4bN0M0	No	No	No	Yes	1+	f	–	–
6	F	70	anaplastic	2.5	T4aN1bM0	Yes	No	Yes	Yes	f	1+	2+	–
7	F	61	anaplastic	1.5	T4bN0M0	No	Yes	Yes	Yes	4+	f	f	f
8	F	59	anaplastic	2.5	T4aN0M0	No	No	No	No	–	–	f	–
9	M	59	anaplastic	4.0	T4aN0M0	No	Yes	No	No	–	–	f	–
10	M	57	anaplastic	2.2	T4aN1bM0	Yes	No	Yes	No	–	f	f	–
11	M	70	anaplastic	3.5	T4aN0M0	No	No	No	No	4+	–	–	–
12	M	79	anaplastic	4.0	T4aN0M0	No	No	No	No	–	–	f	–
13	F	78	anaplastic	7.0	T4bN1bM1	Yes	Yes	Yes	Yes	–	–	3+	–
14	F	74	p. differentiated	3.2	T4aN0M0	No	No	No	No	f	f	f	–
15	M	44	p. differentiated	1.8	T4bN0M0	No	No	No	Yes	1+	f	f	–
16	F	57	p. differentiated	2.4	T4bN1bM0	Yes	No	Yes	Yes	4+	f	f	4+
17	M	80	p. differentiated	1.2	T4aN0M1	No	Yes	No	No	–	–	–	–
18	M	52	p. differentiated	1.8	T4aN0M0	No	No	Yes	No	4+	–	–	–
19	M	65	p. differentiated	1.6	T4aN0M0	No	No	No	No	4+	–	–	–
20	F	66	p. differentiated	4.3	T4aN0M0	No	No	No	No	–	f	f	–
21	F	50	p. differentiated	3.0	T4aN1bM0	Yes	No	Yes	Yes	4+	f	f	3+

P, patient number; F, female; M, male; CT antigen, cancer/testis antigen; MAGE-A, melanoma-associated antigen A; MAGE-C1/CT7, melanoma-associated antigen C1; CTAG1B, cancer/testis antigen 1B; GAGE, G antigen; TNM, tumor-node-metastasis; f, focal.